What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

Osteoporosis International

Volumn 21, Issue 11, 2010, Pages 1793-1802

  Miller, P D ^b   Derman, R J ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Anti resorptive; Estrogens; Nonvertebral fractures; Osteoporosis; Selective estrogen receptor modulators; Vertebral fractures

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; LASOFOXIFENE; OSPEMIFENE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE FRAGILITY; BONE METABOLISM; FEMALE; FRACTURE; HORMONAL THERAPY; HUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78149414618     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1208-3     Document Type: Review

References (115)

1. M Gambacciani F Vacca 2004 Postmenopausal osteoporosis and hormone replacement therapy Minerva Med 95 507 520 1:STN:280:DC%2BD2M7lt1aqtQ%3D%3D 15785435
2. Z Cole E Dennison C Cooper 2008 Update on the treatment of post-menopausal osteoporosis Br Med Bull 86 129 143 1:CAS:528: DC%2BD1cXmvFSkur0%3D 18477578
3. North American Menopause Society 2006 Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society Menopause 13 340 367
4. C Cooper 1999 Epidemiology of osteoporosis Osteoporos Int 9 S2 S8 10525719
5. O Johnell JA Kanis 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726 1733 1:STN:280:DC%2BD28nitVSksQ%3D%3D 16983459
6. JA Sunyecz R Derman 2007 Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists Obstet Gynecol Surv 62 407 416 17511895
7. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 521 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D 19190316
8. MF Delaney 2006 Strategies for the prevention and treatment of osteoporosis during early postmenopause Am J Obstet Gynecol 194 S12 S23 16448872
9. PD Miller 2008 Anti-resorptives in the management of osteoporosis Best Pract Res Clin Endocrinol Metab 22 849 868 1:CAS:528:DC%2BD1cXhsVWmsbnK 19028360
10. AB Hodsman DC Bauer DW Dempster L Dian DA Hanley ST Harris DL Kendler MR McClung PD Miller WP Olszynski E Orwoll CK Yuen 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 688 703 1:CAS:528: DC%2BD2MXps1Kit7g%3D 15769903
11. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/Clinicians- Guide.htm, Accessed 28 October 2009
12. World Health Organization Collaborating Centre for Metabolic Bone Diseases (2008) FRAX® WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/. Accessed 28 October 2009
13. JA Kanis A Oden H Johansson F Borgstrom O Strom E McCloskey 2009 FRAX® and its applications to clinical practice Bone 44 734 743 19195497
14. K Iba J Takada N Hatakeyama M Kaya S Isogai H Tsuda H Obata S Miyano T Yamashita 2006 Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture J Orthop Sci 11 446 449 17013730
15. HK Kamel 2005 Secondary prevention of hip fractures among the hospitalized elderly: are we doing enough? J Clin Rheumatol 11 68 71 16357705
16. P Vestergaard L Rejnmark L Mosekilde 2005 Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark Osteoporos Int 16 134 141 15197546
17. SR Cummings DB Karpf F Harris HK Genant K Ensrud AZ LaCroix DM Black 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 1:CAS:528:DC%2BD38XhvVWkurk%3D 11893367
18. LJ Melton III M Thamer NF Ray JK Chan CH Chesnut III TA Einhorn CC Johnston LG Raisz SL Silverman ES Siris 1997 Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation J Bone Miner Res 12 16 23 9240721
19. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 1:CAS:528: DC%2BD3sXkslOhsb0%3D 12817758
20. PD Miller 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction Curr Osteoporos Rep 3 103 110 16131430
21. S Sarkar BH Mitlak M Wong JL Stock DM Black KD Harper 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1 10 1:CAS:528:DC%2BD38XktFyisg%3D%3D 11771654
22. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236 1:STN:280:DC%2BD3c%2Fpslymug%3D%3D 10634392
23. SA Wainwright LM Marshall KE Ensrud JA Cauley DM Black TA Hillier MC Hochberg MT Vogt ES Orwoll 2005 Hip fracture in women without osteoporosis J Clin Endocrinol Metab 90 2787 2793 1:CAS:528:DC%2BD2MXkt1Wgtrk%3D 15728213
24. ES Siris PD Miller E Barrett-Connor KG Faulkner LE Wehren TA Abbott ML Berger AC Santora LM Sherwood 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment JAMA 286 2815 2822 1:STN:280: DC%2BD3MjgtVGmug%3D%3D 11735756
25. SC Schuit KM van der AE Weel CE de Laet H Burger E Seeman A Hofman AG Uitterlinden JP Van Leeuwen HA Pols 2004 Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study Bone 34 195 202 1:STN:280:DC%2BD2c%2FltVCjsg%3D%3D 14751578
26. P Garnero 2008 Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring Mol Diagn Ther 12 157 170 1:CAS:528:DC%2BD1cXovFKqtbg%3D 18510379
27. Kanis JA, on behalf of the World Health Organization Scientific Group Assessment of Osteoporosis at the Primary Health Care Level (2008) World Health Organization Collaborating Centre for Metabolic Bone Diseases. Technical report. Sheffield, UK
28. JA Kanis O Johnell A Oden H Johansson E McCloskey 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D 18292978
29. NB Watts B Ettinger MS LeBoff 2009 FRAX facts J Bone Miner Res 24 975 979 19364271
30. B Dawson-Hughes on behalf of the National Osteoporosis Foundation Guide Committee 2008 A revised clinician's guide to the prevention and treatment of osteoporosis J Clin Endocrinol Metab 93 2463 2465 1:CAS:528:DC%2BD1cXoslyktLs%3D 18544615
31. S Baim PD Miller 2009 Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw J Bone Miner Res 24 561 574 1:CAS:528:DC%2BD1MXksF2lu7k%3D 19257812
32. S Cremers JP Bilezikian P Garnero 2008 Bone markers-new aspects Clin Lab 54 461 471 1:CAS:528:DC%2BD1MXktlKrtbs%3D 19216252
33. MR McClung 2003 Bisphosphonates Endocrinol Metab Clin North Am 32 253 271 1:CAS:528:DC%2BD3sXjtFOjsbc%3D 12699302
34. American Association of Clinical Endocrinologists (2008) American Association of Clinical Endocrinologists (AACE) position statement on hormone replacement therapy (HRT) and cardiovascular risk. http://www.aace.com/pub/pdf/ guidelines/HRTCVRISKposition-statement.pdf. Accessed 28 October 2009
35. RL Bushardt JL Turner KR Ragucci DG Askins Jr 2006 Non-estrogen treatments for osteoporosis: an evidence-based review JAAPA 19 25 30 17243258
36. BM Tang GD Eslick C Nowson C Smith A Bensoussan 2007 Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 370 657 666 1:CAS:528:DC%2BD2sXpsFWrsbc%3D 17720017
37. CHI Chesnut A Skag C Christiansen R Recker JA Stakkestad A Hoiseth D Felsenberg H Huss J Gilbride RC Schimmer PD Delmas 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 1:CAS:528: DC%2BD2cXntFGqurw%3D
38. S Boonen D Vanderschueren K Venken K Milisen M Delforge P Haentjens 2008 Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance J Intern Med 264 315 332 1:CAS:528:DC%2BD1cXht1Omt7%2FK 18823505
39. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007 (Pubitemid 46698462)
40. DB Karpf DR Shapiro E Seeman KE Ensrud CC Johnston Jr S Adami ST Harris ACII Santora LJ Hirsch L Oppenheimer D Thompson 1997 Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups JAMA 277 1159 1164 1:CAS:528:DyaK2sXis1eqsb8%3D 9087473
41. ST Harris WA Blumentals PD Miller 2008 Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies Curr Med Res Opin 24 237 245 1:CAS:528:DC%2BD1cXhvVOgtL0%3D 18047776
42. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut III J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10527181
43. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier J-Y Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 11172164
44. RS Bobba K Beattie B Parkinson D Kumbhare JD Adachi 2006 Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease Drug Saf 29 1133 1152 1:CAS:528:DC%2BD2sXhtVCmsrk%3D 17147460
45. B Cryer DC Bauer 2002 Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77 1031 1043 12374247
46. FOSAMAX® (alendronate sodium) tablets and oral solution [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2007
47. ACTONEL® (risedronate sodium tablets) [package insert]. Cincinnati, OH: Proctor & Gamble Pharmaceuticals, Inc.; 2007
48. SL Silverman DT Gold 2008 Compliance and persistence with osteoporosis therapies Curr Rheumatol Rep 10 118 122 18460266
49. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg RF Gagel V Gilsanz T Guise S Koka LK McCauley J McGowan MD McKee S Mohla DG Pendrys LG Raisz SL Ruggiero DM Shafer L Shum SL Silverman CH Van Poznak N Watts SB Woo E Shane 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 17663640
50. SL Ruggiero TB Dodson LA Assael R Landesberg RE Marx B Mehrotra 2009 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 2 12 19371809
51. EM Lewiecki SL Silverman 2006 Redefining osteoporosis treatment: who to treat and how long to treat Arq Bras Endocrinol Metabol 50 694 704 17117295
52. DH Solomon L Rekedal SM Cadarette 2009 Osteoporosis treatments and adverse events Curr Opin Rheumatol 21 363 368 19412101
53. AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 18448990
54. JP Schneider 2009 Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk Geriatrics 64 18 23 19256578
55. RA Lobo S Belisle WT Creasman NR Frankel NF Goodman JE Hall SL Ivey S Kingsberg R Langer R Lehman DB McArthur V Montgomery-Rice M Notelovitz GS Packin RW Rebar M Rousseau RS Schenken DL Schneider K Sherif S Wysocki 2006 Should symptomatic menopausal women be offered hormone therapy? MedGenMed 8 40 17410686
56. M Gass 2008 Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy Cleve Clin J Med 75 S13 S16 18693638
57. JA Cauley J Robbins Z Chen SR Cummings RD Jackson AZ LaCroix M LeBoff CE Lewis J McGowan J Neuner M Pettinger ML Stefanick J Wactawski-Wende NB Watts 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial JAMA 290 1729 1738 1:CAS:528:DC%2BD3sXnvVyiu70%3D 14519707 (Pubitemid 37430623)
58. GL Anderson M Limacher AR Assaf T Bassford SA Beresford H Black D Bonds R Brunner R Brzyski B Caan R Chlebowski D Curb M Gass J Hays G Heiss S Hendrix BV Howard J Hsia A Hubbell R Jackson KC Johnson H Judd JM Kotchen L Kuller AZ LaCroix D Lane RD Langer N Lasser CE Lewis J Manson K Margolis J Ockene MJ O'Sullivan L Phillips RL Prentice C Ritenbaugh J Robbins JE Rossouw G Sarto ML Stefanick HL Van J Wactawski-Wende R Wallace S Wassertheil-Smoller 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 1701 1712 1:CAS:528:DC%2BD2cXjt1WktLw%3D 15082697
59. RD Jackson J Wactawski-Wende AZ LaCroix M Pettinger RA Yood NB Watts JA Robbins CE Lewis SA Beresford MG Ko MJ Naughton S Satterfield T Bassford 2006 Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial J Bone Miner Res 21 817 828 1:CAS:528: DC%2BD28XlvVamtb4%3D 16753012
60. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397
61. SL Hendrix S Wassertheil-Smoller KC Johnson BV Howard C Kooperberg JE Rossouw M Trevisan A Aragaki AE Baird PF Bray JE Buring MH Criqui D Herrington JK Lynch SR Rapp J Torner 2006 Effects of conjugated equine estrogen on stroke in the Women's Health Initiative Circulation 113 2425 2434 1:CAS:528: DC%2BD28XksFKgur8%3D 16702472 (Pubitemid 43948050)
62. North American Menopause Society 2008 Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society Menopause 15 584 602
63. B Lees JC Stevenson 2001 The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone Osteoporos Int 12 251 258 1:CAS:528:DC%2BD3MXltFGksLo%3D 11420773
64. R Lindsay JC Gallagher M Kleerekoper JH Pickar 2002 Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 287 2668 2676 1:CAS:528: DC%2BD38XjvVygtbg%3D 12020302
65. R Lindsay JC Gallagher M Kleerekoper JH Pickar 2005 Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women Osteoporos Int 16 372 379 1:CAS:528:DC%2BD2MXisVCitrg%3D 15654581
66. J Heikkinen R Vaheri P Kainulainen U Timonen 2000 Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens Osteoporos Int 11 929 937 1:CAS:528:DC%2BD3MXovFeltg%3D%3D 11193245
67. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645 1:CAS:528: DyaK1MXlvVKqurg%3D 10517716
68. PD Delmas KE Ensrud JD Adachi KD Harper S Sarkar C Gennari JY Reginster HA Pols RR Recker ST Harris W Wu HK Genant DM Black R Eastell 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 3609 3617 1:CAS:528:DC%2BD38XmtF2gsLg%3D 12161484
69. ES Siris ST Harris R Eastell JR Zanchetta S Goemaere A ez-Perez JL Stock J Song Y Qu PM Kulkarni SR Siddhanti M Wong SR Cummings 2005 Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) Study J Bone Miner Res 20 1514 1524 1:CAS:528:DC%2BD2MXhtVOltrrP 16059623
70. UA Liberman MC Hochberg P Geusens A Shah J Lin A Chattopadhyay PD Ross 2006 Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials Int J Clin Pract 60 1394 1400 1:CAS:528:DC%2BD28Xhtlajt7%2FN 17026515
71. E Barrett-Connor JA Cauley PM Kulkarni A Sashegyi DA Cox MJ Geiger 2004 Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial J Bone Miner Res 19 1270 1275 1:CAS:528:DC%2BD2cXntFGquro%3D 15231013
72. E Barrett-Connor L Mosca P Collins MJ Geiger D Grady M Kornitzer MA McNabb NK Wenger 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 125 137 1:CAS:528: DC%2BD28Xmsl2ktrs%3D 16837676 (Pubitemid 44050394)
73. VG Vogel JP Costantino DL Wickerham WM Cronin RS Cecchini JN Atkins TB Bevers L Fehrenbacher ER Pajon Jr JL Wade III A Robidoux RG Margolese J James SM Lippman CD Runowicz PA Ganz SE Reis W Caskill-Stevens LG Ford VC Jordan N Wolmark 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2727 2741 1:CAS:528: DC%2BD28XmtFOltLc%3D 16754727
74. GC Davies WJ Huster Y Lu L Plouffe Jr M Lakshmanan 1999 Adverse events reported by postmenopausal women in controlled trials with raloxifene Obstet Gynecol 93 558 565 1:CAS:528:DyaK1MXit1Ohur4%3D 10214833
75. C Gennari D Agnusdei 1994 Calcitonins and osteoporosis Br J Clin Pract 48 196 200 1:STN:280:DyaK2M%2FgtFahuw%3D%3D 7917799
76. SL Silverman 2008 Calcitonin Endocrinol Metab Clin North Am 32 273 284
77. CH Chesnut III M Azria S Silverman M Engelhardt M Olson L Mindeholm 2008 Salmon calcitonin: a review of current and future therapeutic indications Osteoporos Int 19 479 491 18071651
78. CHI Chesnut S Silverman K Andriano H Genant A Gimona S Harris D Kiel M LeBoff M Maricic P Miller C Moniz M Peacock P Richardson N Watts D Baylink 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 109 267 276 1:CAS:528:DC%2BD3cXms1Wku70%3D 10996576
79. GP Lyritis GV Ioannidis T Karachalios N Roidis E Kataxaki N Papaioannou J Kaloudis A Galanos 1999 Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study Clin J Pain 15 284 289 1:STN:280:DC%2BD3c%2FotlGntA%3D%3D 10617256
80. LA Blau JD Hoehns 2003 Analgesic efficacy of calcitonin for vertebral fracture pain Ann Pharmacother 37 564 570 1:CAS:528:DC%2BD3sXjtFKrsrs%3D 12659616
81. Miacalcin® (calcitonin-salmon) nasal spray [package insert]. Huningue, France: Novartis Pharma S.A.S.; 2006
82. PD Miller AA Chines C Christiansen HC Hoeck DL Kendler EM Lewiecki G Woodson AB Levine G Constantine PD Delmas 2008 Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 525 535 1:CAS:528:DC%2BD1cXltFyhsb8%3D 18072873
83. SL Silverman C Christiansen HK Genant S Vukicevic JR Zanchetta TJ de Villiers GD Constantine AA Chines 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 1:CAS:528:DC%2BD1MXosVylsbo%3D 18665787
84. MR McClung E Siris S Cummings M Bolognese M Ettinger A Moffett R Emkey W Day V Somayaji A Lee 2006 Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Menopause 13 377 386 16735934
85. R Eastell DM Reid S Vukicevic J Thompson D Thompson SR Cummings PD Delmas 2008 The effects of lasofoxifene on bone turnover markers: the PEARL trial J Bone Miner Res 23 S81 Abstract 1287
86. Gass M, Portman D, Bachmann G, Moffett A, Symons J (2004) Clinical signs of vaginal atrophy are improved by the SERM, lasofoxifene. Menopause 11:670, Abstract P-68
87. SR Cummings R Eastell K Ensrud DM Reid S Vukicevic A LaCroix U Sriram D Thompson JR Thompson PD Delmas 2008 The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial J Bone Miner Res 23 S81 Abstract 1288
88. J Komi KS Lankinen M DeGregorio J Heikkinen S Saarikoski M Tuppurainen K Halonen R Lammintausta K Vaananen O Ylikorkala R Erkkola 2006 Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab 24 314 318 1:CAS:528: DC%2BD28XmsVShtro%3D 16816926
89. J Komi KS Lankinen P Harkonen MW DeGregorio S Voipio S Kivinen R Tuimala T Vihtamaki K Vihko O Ylikorkala R Erkkola 2005 Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause 12 202 209 15772568
90. SK Voipio J Komi L Kangas K Halonen MW DeGregorio RU Erkkola 2002 Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women Maturitas 43 207 214 1:CAS:528:DC%2BD38Xoslansrs%3D 12443837
91. O Ylikorkala B Cacciatore K Halonen R Lassila R Lammintausta EM Rutanen J Heikkinen J Komi 2003 Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women Menopause 10 440 447 14501606
92. R Lindsay JC Gallagher R Kagan JH Pickar G Constantine 2009 Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil Steril 92 1045 1052 1:CAS:528:DC%2BD1MXhsFaqtb7L 19635616
93. RA Lobo JV Pinkerton ML Gass MH Dorin S Ronkin JH Pickar G Constantine 2009 Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertil Steril 92 1025 1038 1:CAS:528:DC%2BD1MXhsFaqtb7J 19635615
94. JV Pinkerton WH Utian GD Constantine S Olivier JH Pickar 2009 Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 1116 1124 19546826
95. EM Lewiecki PD Miller MR McClung SB Cohen MA Bolognese Y Liu A Wang S Siddhanti LA Fitzpatrick 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711
96. SR Cummings MJ San MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutilek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655
97. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett M Peacock PD Miller SN Lederman CH Chesnut D Lain AJ Kivitz DL Holloway C Zhang MC Peterson PJ Bekker 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394 (Pubitemid 43290920)
98. BL Riggs LC Hartmann 2003 Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice N Engl J Med 348 618 629 1:CAS:528:DC%2BD3sXhtVyqtLs%3D 12584371
99. BS Komm CR Lyttle 2001 Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation Ann N Y Acad Sci 949 317 326 1:CAS:528:DC%2BD38XnsFajug%3D%3D 11795370
100. JV Pinkerton DF Archer WH Utian JC Menegoci AB Levine AA Chines GD Constantine 2009 Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 1102 1108 19546825
101. DF Archer JV Pinkerton WH Utian JC Menegoci TJ de Villiers CK Yuen AB Levine AA Chines GD Constantine 2009 Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 1109 1115 19543129
102. JA Kanis H Johansson A Oden EV McCloskey 2009 Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049 1054 1:CAS:528:DC%2BD1MXlslWisrw%3D 19254788
103. Pfizer Inc (2008) FABLYN® (lasofoxifene tartrate) 0.5 mg tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02- Pfizer.pdf, Accessed 10 December 2009
104. BS Komm 2008 A new approach to menopausal therapy: the tissue selective estrogen complex Reprod Sci 15 984 992 1:CAS:528:DC%2BD1MXmsVarsA%3D%3D 19088368
105. JH Pickar I-T Yeh G Bachmann L Speroff 2009 Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil Steril 92 1018 1024 1:CAS:528:DC%2BD1MXhsFaqtb7I 19635613
106. DF Archer V Lewis BR Carr S Olivier JH Pickar 2009 Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil Steril 92 1039 1044 1:CAS:528:DC%2BD1MXhsFaqtb7K 19635614
107. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH (2010) A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause (in press)
108. PD Miller 2009 Denosumab: anti-RANKL antibody Curr Osteoporos Rep 7 18 22 19239825
109. PD Miller MA Bolognese EM Lewiecki MR McClung B Ding M Austin Y Liu MJ San Amg Bone Loss Study Group 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 222 229 1:CAS:528:DC%2BD1cXosVOitrk%3D 18539106
110. RD Jackson AZ LaCroix M Gass RB Wallace J Robbins CE Lewis T Bassford SA Beresford HR Black P Blanchette DE Bonds RL Brunner RG Brzyski B Caan JA Cauley RT Chlebowski SR Cummings I Granek J Hays G Heiss SL Hendrix BV Howard J Hsia FA Hubbell KC Johnson H Judd JM Kotchen LH Kuller RD Langer NL Lasser MC Limacher S Ludlam JE Manson KL Margolis J McGowan JK Ockene MJ O'Sullivan L Phillips RL Prentice GE Sarto ML Stefanick HL Van J Wactawski-Wende E Whitlock GL Anderson AR Assaf D Barad 2006 Calcium plus vitamin D supplementation and the risk of fractures N Engl J Med 354 669 683 1:CAS:528:DC%2BD28XhsVWksr0%3D 16481635 (Pubitemid 43247138)
111. RP Heaney 2006 Calcium intake and disease prevention Arq Bras Endocrinol Metabol 50 685 693 17117294
112. MA Moyad 2003 Osteoporosis. Part III-Not just for bone loss: potential benefits of calcium and vitamin D for overall general health Urol Nurs 23 69 74 12677721
113. HA Bischoff HB Stahelin W Dick R Akos M Knecht C Salis M Nebiker R Theiler M Pfeifer B Begerow RA Lew M Conzelmann 2003 Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial J Bone Miner Res 18 343 351 1:CAS:528:DC%2BD3sXht1Sktrs%3D 12568412
114. RH Harwood O Sahota K Gaynor T Masud DJ Hosking 2004 A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study Age Ageing 33 45 51 14695863
115. M Pfeifer B Begerow HW Minne C Abrams D Nachtigall C Hansen 2000 Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women J Bone Miner Res 15 1113 1118 1:CAS:528:DC%2BD3cXktFKhurs%3D 10841179